These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23734031)

  • 1. US approves "new class" of diabetes drug, under review in Canada.
    Lange-Chenier H
    CMAJ; 2013 Jul; 185(10):E470. PubMed ID: 23734031
    [No Abstract]   [Full Text] [Related]  

  • 2. Canagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2013 May; 70(10):834. PubMed ID: 23640337
    [No Abstract]   [Full Text] [Related]  

  • 3. Canagliflozin: a new drug for type 2.
    Goldman-Levine J
    Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
    [No Abstract]   [Full Text] [Related]  

  • 4. [Canagliflozin. For treating diabetes].
    Sabourin G
    Perspect Infirm; 2013; 10(3):59. PubMed ID: 23705284
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
    Said S; Hernandez GT
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug approved for type 2 diabetes.
    Nurs Times; 2014 Jul 2-8; 110(27):4. PubMed ID: 25095559
    [No Abstract]   [Full Text] [Related]  

  • 8. Type 2 diabetes mellitus and Invokana: an FDA approved drug.
    Akhtar N
    Curr Diabetes Rev; 2013 Nov; 9(6):478-90. PubMed ID: 24160357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 10. New diabetes drugs go beyond insulin to flush out excess sugar.
    Heger M
    Nat Med; 2011 Jun; 17(6):636. PubMed ID: 21647124
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
    Mehr SR; Zimmerman MP
    Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
    [No Abstract]   [Full Text] [Related]  

  • 12. Canagliflozin: Improving diabetes by making urine sweet.
    Vouyiouklis M
    Cleve Clin J Med; 2013 Nov; 80(11):683-7. PubMed ID: 24186885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

  • 14. [Introduction].
    García SD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
    Med Lett Drugs Ther; 2014; 56(1457):124-5. PubMed ID: 25461230
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
    Lamos EM; Younk LM; Davis SN
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):763-75. PubMed ID: 23590413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.